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Introduction:
Sickle cell disease is the most common genetic disease globally, with about 100,000 being in the
United States. Survival of adult patients with sickle cell disease (SCD) has increased
progressively since the 1970’s. Newborn screening, prophylactic antibiotics, newer vaccines,
newer analgesics, safer blood transfusion, chelation therapy and hydroxyurea are some of the
reasons for this change in longevity 1-4. Patients with SCD in their sixth, seventh or eighth decade
have been described previously5,6. Platt et al. reported that the median age of survival for males
with sickle cell anemia was 42 years and for females 48 years.
Aging patients with SCD are at risk to develop comorbiditi1-4es that are not due to SCD itself,
but they also become more at risk for developing comorbid conditions that were not previously
seen or were rare in this patient population. These include, among other things, diabetes mellitus,
rheumatoid arthritis, osteoarthritis, systemic lupus erythematosus, obesity, AIDS, inflammatory
bowel disease, hypertension, malignant disorders, etc. The objective of this paper is to review the
prevalence of malignancy in aging patients with SCD in our institution in the presence or
absence of Hydroxyurea.

The first case of cancer documented in adult SCD patient was in 1953 By Goldin7. In 1986, Stricker
el al8 did a literature review of cancer cases documented so far in adult and pediatric population
and added 4 of their own cases. In their report, they suggested that hematologic malignancies were
rare events in sickle cell disease population, based on some reports from Africa, Jamaica, Saudi
Arabia and United States

9-11

. They attributed this low incidence to be related to short longevity

due to complicated disease before getting the chance to develop neoplasia. However, they expected
with longer survival, there may be increase in hematologic malignancies due to the hypothesis of
increased oncogene expression occurring during erythropoiesis stimulation seen in rats. In 1997,
Dawkins et Al

12

were the first to attempt to calculate cancer incidence and mortality in SCD

patients. The cancer incidence rate was 5/2,864 and mortality rate was 3/2,873. However, there
was no control group and they used limited population.
Since then, many case reports and small reviews tried to document cancer cases with no real
study assessing the incidence and correlation with sickle cell disease itself. The first study
comparing cancer rates in a sickle cell disease cohort and a control cohort was done in 2016 in
England by Seminog et al13 .Using English national dataset of hospital admissions and deaths
from 1999 to 2011, 7512 SCD patient were identified. Comparing the sickle cell disease cohort
with the cohort without sickle cell disease, the rate ratio for all cancers combined was 2.1, with
significantly higher rate of hematological malignancies, including Hodgkin’s lymphoma, nonHodgkin’s lymphoma, multiple myeloma, lymphoid leukemia and myeloid leukemia among
SCD patients. Four solid tumors showed elevated rate ratios in SCD population as well: colon
cancer, non-melanoma skin cancer, kidney cancer and thyroid cancer. Again, listing of possible
underlying mechanism of cancer in this specific population included: endothelial damage,
systemic inflammation, hypoxia, acidosis and compromised apoptosis; exposure to bone marrow
transplantation, transfusion-related immunomodulation, and transmission of infections such as
viral hepatitis and HIV. Hydrea was mentioned as one possibility, however, no clinical trials had
proven it by that time.
A more recent analysis released in 2017 by Brunson et Al 14 compared cancer incidence in SCD
patient to the general population. 6,423 SCD patients were identified using California database
from the Office of Statewide Health Planning and Development. Compared to the California
population, SCD patients had a 72% increased risk of hematologic malignancies and 38%

reduced risk of solid tumors. There was two-fold increased risk of leukemia specifically acute
myeloid leukemia and chronic lymphocytic leukemia. This risk was increased by four-fold in
more severe SCD. There was 38% reduced risk of solid tumors, specifically, there was lower risk
of breast cancer and male genital cancers. Cancer incidence was different than England study,
most likely due to different recruitment using highly validated registry data in California study
and not hospital coding like in England study. This study also commented on effect of
Hydroxyurea on cancer incidence and they mentioned no difference in cancer incidence before
and after Hu era use in 1998.
The reduced risk of solid tumors was suggested to be secondary to the ability of sickled
erythrocytes to selectively target hypoxic tumor vascular microenvironment and lead to tumor
micro vessels occlusion. As for the increased risk of hematologic malignancies, there has been
multiple theories behind these findings including Transfusion Related Immune Modulation, iron
overload associated with transfusion, and transfusion related infection, chronic inflammation due
to sickle cell disease itself, increased RBC proliferation and turn over in the marrow, and
possibly hydroxyurea use.
To the best of our knowledge, no studies has been done to evaluate cancer incidence in aging
sickle cell patients, especially in hydroxyurea era.

Case series:
In our study, we are trying to identify malignancies in aging patients with SCD. Looking back in
our records, we identified patients who carry the diagnosis of sickle cell disease and malignancy
before 2020. We used ICD-10 codes. 483 patients with sickle cell disease were seen in our inpatient
and outpatient offices. Among these, 70 were identified with malignancy based on the ICD-10.
Further chart reviews confirmed that only 12 SCD patients had confirmed diagnosis of a
malignancy. Demographic and clinical data of these patients are presented in table 1.
The mean age of the 12 patients studied was 52.2 ± 13.4 years, of the 5 females was 57.8 ± 10.1
and of the 7 males was 48.1 ± 14.0. The mean age of the 7 living patients was 49.3 ± 14.0 years,
of the 6 males was 48.7 ± 15.0 and of the one female was 53 years. The mean age of the 5 deceased
patients was 56.2 ± 11.3 years, of these one was male age 45 years and 4 were females aged 59.0

± 111.0. Although there was no significant difference between females and males in any of these
categories of patients, there is a tendency for females to live longer than males and die older than
males.
In order to clarify the interrelationships among age, malignancy and HU, we divided the patients
into 3 categories as shown in Table 2.
The first group included 2 patients with age ranging from 20-40. Both had hematologic
malignancies (Acute Myelogenous Leukemia (AML) and Multiple myeloma) and both were on
HU in adulthood (Blue column Table 1).
The second group included 6 patients with age ranging from 40-60 years. One of these (patient
C in Table1) had CML(Chronic Myeloid Leukemia), and the 5 other patients were all diagnosed
with solid tumors (oral cavity carcinoma, tongue carcinoma, Renal Cell Carcinoma, pancreatic
and gastro intestinal cancer), 2 of these were on HU in adulthood, and 4 out of the 5 had iron
overload (orange column Table 1)
The third group included 4 patients who were older than 60 years, 2 females and 2 males. Only 1
of these patients was exposed to HU in adulthood. They all had multiple myeloma (yellow
columns, Table 1).
Patients were considered on Hydroxyurea therapy if they have been taking the drug for more
than 6 months. Among the 12 patients, 7 were still alive when we collected data. 6 out of 7 alive
patients were on Hydroxyurea. 5 patients were deceased at the time of data collection, and none
of them was on hydroxyurea therapy. Prior data have shown decrease mortality rate among this
population with hydroxyurea use. Most of our patients who were alive during data collection
were treated with hydroxyurea.

Discussion:
To the best of our knowledge this is the first report about risk of malignancies in aging sickle cell
population with or without HU. Patients 60 years and older were all affected by Multiple
Myeloma. Most of these patients were not on HU. The combination of SCD and multiple

myeloma can have a bad outcome. Both are characterized by hyperviscosity, renal failure, bone
involvement, and sepsis. The diagnosis of multiple myeloma may be missed initially since the
presenting signs and symptom of multiple myeloma may be attributed to VOC or other
complications of SCD. Solid tumors were the majority in patients with age ranging from 40-60
and the majority had SS genotype and had signs of iron overload. The number of patients on
Hydroxyurea was too small so we cannot make any comment on relationship to malignancy or
mortality. It must be emphasized that this study is only one institution experience and the sample
size is too small to make definite conclusions. Most of the studies so far have used data base
analysis to assess incidence of cancer in sickle cell population. Our experience with this method
showed a big mismatch in numbers compared to chart review method. Future studies must be
careful how to interpret results coming from data base analysis. Should we be developing newer
guidelines for cancer screening in this specific population? And now with the approval of new
therapies for SCD, would cancer incidence be changed with time?
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